A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage

Inclusion Criteria: * Subject is at least 18 years of age but no more than 70 years of age. * Subject has at least two non-adjacent teeth in contralateral quadrants of the same jaw with Miller Class I or II buccal recession (≥ 3 mm) that requires soft tissue grafting. (Teeth may be treated with a maximum difference of 2 mm with respect to depth and width). * Females of childbearing potential must have a documented negative urine pregnancy test and must agree to continue acceptable methods of contraception for 6 months post surgery. * Subjects must have read, understood and signed an institutional review board (IRB)-approved Informed Consent Form (ICF). * Subjects must be able and willing to follow study procedures and instructions. Exclusion Criteria: * Subject has extremely prominent root surfaces (\> 1/2 the diameter of the root facial to cortical plate). * Subject has interproximal attachment loss beyond the CEJ. * Subject with teeth that have a Miller Grade 2 or higher mobility. * Subjects with Class V restorations. * Subjects with crowns on the teeth selected for treatment. * Subjects who have had endodontic therapy in the last 6 months on the teeth selected for treatment. * Subjects who have used any tobacco product within the past 3 months. * Subjects with only molar teeth suitable for soft tissue grafting. * Subject has probing pocket depth \>/= 4 mm at either surgical site. * Female subjects who are pregnant or lactating. * Subjects with any systemic conditions (i.e., uncontrolled diabetes mellitus, cancer, HIV, bone metabolic diseases) that could compromise wound healing and preclude periodontal surgery. * Subjects who are currently receiving or have received within two months prior to study entry, systemic corticosteroids, immunosuppressive agents, radiation therapy, and/or chemotherapy which could compromise wound healing and preclude periodontal surgery. * Subjects with the presence of acute infectious lesions. * Subjects taking intramuscular or intravenous bisphosphonates. * Subjects with a known hypersensitivity to bovine collagen and/or iodine (shellfish allergy). * Subjects who have received an investigational drug, device or biological/bioactive treatment within 30 days prior to study enrollment (medical or dental). * Subjects previously treated with Apligraf/CelTx, Dermagraft or any other cell-based product, including autologous tissue at the target site(s) or immediately adjacent teeth. * Subjects, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol